Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma

Trial Profile

Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldesleukin (Primary) ; Busulfan (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Dinutuximab (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Isotretinoin (Primary) ; Levetiracetam (Primary) ; Melphalan (Primary) ; Mesna (Primary) ; Natural killer cell therapy (Primary) ; Sargramostim (Primary) ; Stem cell therapies (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
    • 01 Aug 2023 According to a Renaissance Pharma media release, company will pursue interaction with the FDA and EMA together with other regulatory agencies around the globe to develop the optimal path to submission.
    • 06 Dec 2021 Results (As of November 4, 2020; N= 64) assessing whether combining Dinutuximab throughout therapy improves early response and outcomes in children with newly diagnosed high-risk neuroblastoma, published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top